Standout Papers

Pancreatic Cancer 2001 2026 2009 2017 2.1k
  1. Pancreatic Cancer (2010)
    Manuel Hidalgo New England Journal of Medicine
  2. Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research (2014)
    Manuel Hidalgo, Frédéric Amant et al. Cancer Discovery
  3. Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab (2007)
    Shirin Khambata‐Ford, Christopher R. Garrett et al. Journal of Clinical Oncology
  4. Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies (2001)
    Manuel Hidalgo, Lillian L. Siu et al. Journal of Clinical Oncology
  5. Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial (2011)
    Daniel D. Von Hoff, Ramesh K. Ramanathan et al. Journal of Clinical Oncology
  6. DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer (2009)
    Christine A. Iacobuzio–Donahue, Baojin Fu et al. Journal of Clinical Oncology
  7. Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma (2004)
    Michael B. Atkins, Manuel Hidalgo et al. Journal of Clinical Oncology
  8. Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy (2001)
    Manuel Hidalgo, S. Gail Eckhardt JNCI Journal of the National Cancer Institute
  9. Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (2003)
    Denis Soulières, Neil Senzer et al. Journal of Clinical Oncology
  10. Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study (2005)
    Evanthia Galanis, Jan C. Buckner et al. Journal of Clinical Oncology
  11. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies (2015)
    Ignacio Garrido‐Laguna, Manuel Hidalgo Nature Reviews Clinical Oncology
  12. Addressing the challenges of pancreatic cancer: Future directions for improving outcomes (2014)
    Manuel Hidalgo, Stefano Cascinu et al. Pancreatology

Immediate Impact

1 by Nobel laureates 24 from Science/Nature 145 standout
Sub-graph 1 of 18

Citing Papers

Pancreatic cancer: Advances and challenges
2023 Standout
CDK4 and CDK6 kinases: From basic science to cancer therapy
2022 StandoutScience
58 intermediate papers

Works of Manuel Hidalgo being referenced

CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma
2020
Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models
2011
and 35 more

Author Peers

Author Last Decade Papers Cites
Manuel Hidalgo 18199 12346 7323 443 29.1k
Christine A. Iacobuzio–Donahue 17019 13029 8900 280 28.8k
Ming‐Sound Tsao 14968 16214 8193 644 36.3k
Waun Ki Hong 12563 16651 5447 505 33.5k
Martin Gore 14140 12791 4895 377 29.0k
Daniel D. Von Hoff 23213 19391 8189 816 43.9k
Jean‐Charles Soria 19265 12792 6724 675 34.0k
Richard Pazdur 19104 10270 4972 582 36.2k
Herbert M. Pinedo 15681 11909 3522 569 29.4k
Giampaolo Tortora 13500 9748 4648 619 23.7k
Scott M. Lippman 12512 13300 7757 520 36.3k

All Works

Loading papers...

Rankless by CCL
2026